Maximum quantity allowed is 999
CAS RN: 78351-75-4 | Product Number: C2884
1-(3-Chloroanilino)-4-phenylphthalazine
Purity: >98.0%(GC)
- MY-5445
- 1-(3-Chlorophenyl)amino-4-phenylphthalazine
Size | Unit Price | Saitama (Kawaguchi) | Hyogo (Amagasaki) | Stock in other WH | Shipping Information |
---|---|---|---|---|---|
20MG |
¥5,800
|
20 | 2 | Contact Us | |
100MG |
¥20,000
|
29 | 1 | Contact Us |
* The displayed price is the unit price and does not include consumption tax. The unit prices displayed are the latest and are subject to change without notice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | C2884 |
Purity / Analysis Method | >98.0%(GC) |
Molecular Formula / Molecular Weight | C__2__0H__1__4ClN__3 = 331.80 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
CAS RN | 78351-75-4 |
PubChem Substance ID | 253661527 |
MDL Number | MFCD00209838 |
Appearance | White to Light yellow powder to crystal |
Purity(GC) | min. 98.0 % |
NMR | confirm to structure |
1-(3-Chloroanilino)-4-phenylphthalazine (MY-5445) is a specific inhibitor of cyclic GMP (cGMP) phosphodiesterase type 5 (PDE5). MY-5445 inhibits platelet aggregation by increasing cGMP content.
Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation
M. Hagiwara, T. Endo, T. Kanayama, H. Hidaka, J. Pharmacol. Exp. Ther. 1984, 228, 467.
Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine
J. E. Souness, R. Brazdil, B. K. Diocee, R. Jordan, Br. J. Pharmacol. 1989, 98, 725.
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.